326 related articles for article (PubMed ID: 9843170)
21. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Hicks K; Peng D; Gajewski JL
Bone Marrow Transplant; 2002 Dec; 30(12):975-8. PubMed ID: 12476294
[TBL] [Abstract][Full Text] [Related]
22. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
[TBL] [Abstract][Full Text] [Related]
23. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.
Saxon BR; Shanks D; Jory CB; Williams V
Thromb Haemost; 2001 Oct; 86(4):1126-7. PubMed ID: 11686341
[No Abstract] [Full Text] [Related]
24. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
Brackmann HH; Effenberger W; Hess L; Schwaab R; Oldenburg J
Eur J Haematol Suppl; 1998; 63():18-23. PubMed ID: 9882928
[TBL] [Abstract][Full Text] [Related]
25. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
26. Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.
Carr ME; Loughran TP; Cardea JA; Smith WK; Kuhn JG; Dottore MV
Int J Hematol; 2002 Jan; 75(1):95-9. PubMed ID: 11843300
[TBL] [Abstract][Full Text] [Related]
27. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
[TBL] [Abstract][Full Text] [Related]
28. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Abshire T; Kenet G
Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
[TBL] [Abstract][Full Text] [Related]
29. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Hedner U
Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
[TBL] [Abstract][Full Text] [Related]
30. Intraoperative use of recombinant activated factor VII (rFVIIa).
De Gasperi A
Minerva Anestesiol; 2006 Jun; 72(6):489-94. PubMed ID: 16682921
[TBL] [Abstract][Full Text] [Related]
31. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S111-4. PubMed ID: 9819040
[TBL] [Abstract][Full Text] [Related]
32. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
33. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.
Rodriguez-Merchan EC; Jimenez-Yuste V; Gomez-Cardero P; Alvarez-Roman M; Martin-Salces M; Rodriguez de la Rua A
Haemophilia; 2010 May; 16(102):84-8. PubMed ID: 20536990
[TBL] [Abstract][Full Text] [Related]
34. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
35. Home treatment with recombinant activated factor VII: results from one centre.
Ingerslev J; Thykjaer H; Kudsk Jensen O; Fredberg U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S107-10. PubMed ID: 9819039
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
37. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
Takedani H; Kawahara H; Kajiwara M
Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
[TBL] [Abstract][Full Text] [Related]
38. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
[TBL] [Abstract][Full Text] [Related]
39. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]